Lipanthyl

Fenofibrate, the active ingredient in Lipanthyl, is a fibrate presented as an oral tablet (strength not specified) for oral use. It lowers elevated triglycerides and cholesterol in adults with dyslipidemia.

GNH USA supplies Lipanthyl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lipanthyl (fenofibrate) is used to manage lipid disorders by reducing triglyceride‑rich lipoproteins.

- Hypertriglyceridemia: lowers very high triglyceride levels to reduce pancreatitis risk. - Mixed dyslipidemia: decreases triglycerides and LDL‑cholesterol while modestly raising HDL‑cholesterol. - Primary hypercholesterolemia (adjunct therapy): adds to statin treatment to improve overall lipid profile.

Adverse reactions may occur with fenofibrate therapy and are categorized by frequency.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia. - Elevated liver enzymes: mild increases in ALT or AST. - Muscle pain: myalgia without severe weakness. - Headache: mild to moderate intensity. - Skin reactions: rash or pruritus.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with dark urine. - Hepatotoxicity: significant liver injury with jaundice. - Severe allergic reactions: anaphylaxis or angioedema. - Gallstones: formation of biliary sludge or stones. - Blood dyscrasias: thrombocytopenia or leukopenia.

Before initiating fenofibrate, consider the following safety measures.

- Liver function: assess baseline hepatic enzymes and monitor periodically. - Renal function: evaluate kidney status, especially in patients with impairment. - Muscle health: avoid use with statins or other myotoxic agents without monitoring. - Pregnancy and lactation: use only if the potential benefit justifies the risk. - Drug interactions: review concomitant medications for known interactions. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Fenofibrate may interact with several drug classes; awareness of interaction severity guides management.

Major Interactions (Avoid): - Statins (especially high‑dose simvastatin): increased risk of rhabdomyolysis. - Anticoagulants (warfarin): potentiation of anticoagulant effect, monitor INR. - Bile acid sequestrants: may reduce fenofibrate absorption, separate dosing by at least 2 hours.

Moderate Interactions (Monitor Closely): - Immunosuppressants (cyclosporine, tacrolimus): may raise fenofibrate levels. - Oral hypoglycemics: potential enhancement of glucose‑lowering effect. - Thyroid hormones: possible alteration of thyroid function tests.